{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:49:08Z","timestamp":1789469348299,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"T\u00e9l\u00e9vie-Luxembourg"},{"name":"\u201cRecherche Cancer et Sang\u201d foundation"},{"name":"\u201cRecherches Scienti\ufb01ques Luxembourg\u201d association"},{"name":"\u201cEen H\u00e4erz fir kriibskrank Kanner\u201d association"},{"DOI":"10.13039\/501100006672","name":"Action LIONS \u201cVaincre le Cancer\u201d association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006672","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"crossref","award":["019R1A2C1009231"],"award-info":[{"award-number":["019R1A2C1009231"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MEST of Korea","award":["2011-0030001"],"award-info":[{"award-number":["2011-0030001"]}]},{"name":"Brain Korea (BK21) PLUS program and Creative-Pioneering Researchers Program","award":["370C-20160062"],"award-info":[{"award-number":["370C-20160062"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.phrs.2020.105058","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T15:07:58Z","timestamp":1593529678000},"page":"105058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia"],"prefix":"10.1016","volume":"160","author":[{"given":"H\u00e9l\u00e8ne","family":"Losson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi Reddy","family":"Gajulapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Lernoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aloran","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9borah","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunggu","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christo","family":"Christov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Dicato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Woo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schnekenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Diederich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9976","key":"10.1016\/j.phrs.2020.105058_bib0005","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2020.105058_bib0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2020.105058_bib0015","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1056\/NEJMe1700833","article-title":"Imatinib changed everything","volume":"376","author":"Longo","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105058_bib0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.phrs.2020.105058_bib0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.phrs.2020.105058_bib0030","first-page":"23","article-title":"Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib","volume":"10","author":"Emole","year":"2016","journal-title":"Biologics"},{"key":"10.1016\/j.phrs.2020.105058_bib0035","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.2147\/DDDT.S85050","article-title":"Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations","volume":"10","author":"Keskin","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"7","key":"10.1016\/j.phrs.2020.105058_bib0040","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4161\/cbt.28931","article-title":"SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells","volume":"15","author":"Bu","year":"2014","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.phrs.2020.105058_bib0045","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.biochi.2012.05.012","article-title":"Chromatin-modifying agents in anti-cancer therapy","volume":"94","author":"Seidel","year":"2012","journal-title":"Biochimie"},{"issue":"7","key":"10.1016\/j.phrs.2020.105058_bib0050","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2174\/1568026615666150825141330","article-title":"Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments","volume":"16","author":"Schnekenburger","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"issue":"11","key":"10.1016\/j.phrs.2020.105058_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21111608","article-title":"Natural compound histone deacetylase inhibitors (HDACi): synergy with inflammatory signaling pathway modulators and clinical applications in cancer","volume":"21","author":"Losson","year":"2016","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.phrs.2020.105058_bib0060","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2020.105058_bib0065","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.phrs.2020.105058_bib0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/epi.14.69","article-title":"Histone deacetylase 6 in health and disease","volume":"7","author":"Seidel","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.phrs.2020.105058_bib0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bcp.2015.11.005","article-title":"4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90alpha chaperone activity against prostate cancer","volume":"99","author":"Seidel","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2020.105058_bib0080","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"issue":"Database issue","key":"10.1016\/j.phrs.2020.105058_bib0085","doi-asserted-by":"crossref","first-page":"D1113","DOI":"10.1093\/nar\/gku1057","article-title":"ArrayExpress update--simplifying data submissions","volume":"43","author":"Kolesnikov","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"19","key":"10.1016\/j.phrs.2020.105058_bib0090","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/bioinformatics\/btq431","article-title":"A framework for oligonucleotide microarray preprocessing","volume":"26","author":"Carvalho","year":"2010","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/j.phrs.2020.105058_bib0095","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.105058_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v025.i01","article-title":"FactoMineR: an r package for multivariate analysis","volume":"25","author":"L\u00ea","year":"2008","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.phrs.2020.105058_bib0105","series-title":"R: a Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2010"},{"key":"10.1016\/j.phrs.2020.105058_bib0110","series-title":"ggpubr:\u2019 ggplot2\u2019 Based Publication Ready Plots","author":"Kassambara","year":"2018"},{"key":"10.1016\/j.phrs.2020.105058_bib0115","series-title":"RStudio: Integrated Development for R","author":"RStudio Team","year":"2015"},{"issue":"11","key":"10.1016\/j.phrs.2020.105058_bib0120","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1021\/acs.jmedchem.7b00533","article-title":"Discovery and characterization of R\/S-N-3-cyanophenyl-N\u2019-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1- benzopyran-4-yl)urea, a new histone deacetylase class III inhibitor exerting antiproliferative activity against Cancer cell lines","volume":"60","author":"Schnekenburger","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105058_bib0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.canlet.2018.07.041","article-title":"Hydroxycoumarin OT-55 kills CML cells alone or in synergy with imatinib or Synribo: involvement of ER stress and DAMP release","volume":"438","author":"Mazumder","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2020.105058_bib0130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.phrs.2017.11.004","article-title":"Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways","volume":"129","author":"Lernoux","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.105058_bib0135","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2013.09.026","article-title":"Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases","volume":"343","author":"Seidel","year":"2014","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.phrs.2020.105058_bib0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1871520614666141202143757","article-title":"Dual induction of mitochondrial apoptosis and senescence in chronic myelogenous leukemia by myrtucommulone A","volume":"15","author":"Grandjenette","year":"2015","journal-title":"Anticancer Agents Med. Chem."},{"issue":"2019","key":"10.1016\/j.phrs.2020.105058_bib0145","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.2147\/OTT.S197535","article-title":"Tumor necrosis factor alpha knockout impaired tumorigenesis in chronic myeloid leukemia cells partly by metabolism modification and miRNA regulation","volume":"12","author":"Shen","year":"2019","journal-title":"Onco. Ther."},{"issue":"136","key":"10.1016\/j.phrs.2020.105058_bib0150","first-page":"e57490","article-title":"Preclinical assessment of the bioactivity of the anticancer coumarin OT48 by spheroids, colony formation assays, and zebrafish xenografts","author":"Lee","year":"2018","journal-title":"J. Vis. Exp."},{"issue":"3","key":"10.1016\/j.phrs.2020.105058_bib0155","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"51","key":"10.1016\/j.phrs.2020.105058_bib0160","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"26","key":"10.1016\/j.phrs.2020.105058_bib0165","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1021\/acs.biochem.8b00367","article-title":"Entropy as a driver of selectivity for inhibitor binding to histone deacetylase 6","volume":"57","author":"Porter","year":"2018","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.phrs.2020.105058_bib0170","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.4161\/cc.10.9.15486","article-title":"Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform","volume":"10","author":"Marcato","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.phrs.2020.105058_bib0175","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2147\/DDDT.S191303","article-title":"Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities","volume":"13","author":"Flis","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2020.105058_bib0180","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit. Care"},{"issue":"5","key":"10.1016\/j.phrs.2020.105058_bib0185","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/epi.11.73","article-title":"Epigenomics of leukemia: from mechanisms to therapeutic applications","volume":"3","author":"Florean","year":"2011","journal-title":"Epigenomics"},{"key":"10.1016\/j.phrs.2020.105058_bib0190","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2017.07.006","article-title":"Epigenetic dysregulation in chronic myeloid leukaemia: a myriad of mechanisms and therapeutic options","volume":"51","author":"Koschmieder","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"16","key":"10.1016\/j.phrs.2020.105058_bib0195","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2020.105058_bib0200","doi-asserted-by":"crossref","first-page":"e89080","DOI":"10.1371\/journal.pone.0089080","article-title":"Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia","volume":"9","author":"Okabe","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.phrs.2020.105058_bib0205","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/cas.12965","article-title":"Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells","volume":"107","author":"Matsuda","year":"2016","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.phrs.2020.105058_bib0210","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2008-03-143644","article-title":"HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells","volume":"112","author":"Rao","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.phrs.2020.105058_bib0215","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1002\/jcp.26786","article-title":"Mcl-1 targeting could be an intriguing perspective to cure cancer","volume":"233","author":"De Blasio","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105058_bib0220","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.yexcr.2018.07.017","article-title":"HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1","volume":"370","author":"Bamodu","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"7607","key":"10.1016\/j.phrs.2020.105058_bib0225","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.phrs.2020.105058_bib0230","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/0145-2126(93)90161-D","article-title":"Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line","volume":"17","author":"Law","year":"1993","journal-title":"Leuk. Res."},{"issue":"14","key":"10.1016\/j.phrs.2020.105058_bib0235","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.phrs.2020.105058_bib0240","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/mnfr.201300201","article-title":"Curcumin as a regulator of epigenetic events","volume":"57","author":"Teiten","year":"2013","journal-title":"Mol. Nutr. Food Res."},{"issue":"11","key":"10.1016\/j.phrs.2020.105058_bib0245","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.bmc.2010.04.047","article-title":"Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli","volume":"18","author":"Lamoral-Theys","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105058_bib0250","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3389\/fphys.2017.00436","article-title":"Impact of chemical analogs of 4-Hydroxybenzoic acid on coenzyme q biosynthesis: from inhibition to bypass of coenzyme q deficiency","volume":"8","author":"Pierrel","year":"2017","journal-title":"Front. Physiol."},{"issue":"9","key":"10.1016\/j.phrs.2020.105058_bib0255","doi-asserted-by":"crossref","DOI":"10.3390\/nu11092221","article-title":"The paradox of coenzyme Q10 in aging","volume":"11","author":"Diaz-Casado","year":"2019","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.phrs.2020.105058_bib0260","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020318","article-title":"HDAC6-an emerging target against chronic myeloid leukemia?","volume":"12","author":"Losson","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.phrs.2020.105058_bib0265","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ijc.32169","article-title":"Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models","volume":"145","author":"Depetter","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2020.105058_bib0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082337","article-title":"The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease","volume":"19","author":"Cosenza","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2020.105058_bib0275","first-page":"207","article-title":"Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia","volume":"23","author":"Drexler","year":"1999","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.phrs.2020.105058_bib0280","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ejh.12597","article-title":"Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia","volume":"96","author":"Lin","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"8","key":"10.1016\/j.phrs.2020.105058_bib0285","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","article-title":"E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy","volume":"102","author":"Claudiani","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.phrs.2020.105058_bib0290","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.phrs.2020.105058_bib0295","first-page":"1479","article-title":"Prognostic implication of BCR-ABL fusion transcript variants in chronic myeloid leukemia (CML) treated with imatinib. A first of its kind study on CML patients of Kashmir","volume":"19","author":"Azad","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.phrs.2020.105058_bib0300","first-page":"803","article-title":"Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia","volume":"4","author":"de Lemos","year":"2005","journal-title":"Genet. Mol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820313669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820313669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:19:26Z","timestamp":1760912366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820313669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":60,"alternative-id":["S1043661820313669"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105058","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105058"}}